HMGA2 Is a Useful Marker of Vulvovaginal Aggressive Angiomyxoma But May Be Positive in Other Mesenchymal Lesions at This Site
| Autor: | Robert Harkness, W. Glenn McCluggage |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Pathology medicine.medical_specialty Stromal cell Vaginal Neoplasms Pathology and Forensic Medicine 03 medical and health sciences Neoplasms Muscle Tissue 0302 clinical medicine Aggressive angiomyxoma Polyps Neoplasms Fibroepithelial medicine Biomarkers Tumor Humans Vulvovaginal Region Vulvar Neoplasms business.industry HMGA2 Protein Obstetrics and Gynecology medicine.disease Immunohistochemistry Staining 030104 developmental biology 030220 oncology & carcinogenesis Smooth Muscle Tumor Female Differential diagnosis Angiomyxoma business Myxoma Myofibroblastoma |
| Zdroj: | International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists. 40(2) |
| ISSN: | 1538-7151 |
| Popis: | Aggressive angiomyxoma (AA) is a rare mesenchymal neoplasm occurring almost exclusively in the vulvovaginal region and which has a wide differential diagnosis. It has previously been suggested that the nuclear transcription factor HMGA2 is a useful marker of AA, although the number of studies is limited. We investigated HMGA2 immunoreactivity in a large series (n=284) of vulvovaginal mesenchymal lesions. HMGA2 nuclear staining was classified as diffuse (≥50%), focal ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|